Skip to main content
Midas Edge

Benitec Biopharma Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

BNTC$9.87+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

NumberDescription of Document
31.1Statement of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2Statement of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1Statement of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2Statement of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INSInline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document
101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104Cover page formatted as Inline XBRL and contained in Exhibit 101
  • Filed herewith.

** Furnished, not filed.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.